Achieved proof-of-mechanism for Wave's RNA editing platform; restoring levels of wild-type (edited) M-AAT that are consistent with the heterozygous "MZ” genotype with low risk of AATD lung and liver ...
CAMBRIDGE, Mass., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform ...
Researchers have developed RNA therapeutics, called micelles, that can delivery chemotherapeutic drugs to metastasized tumors in mouse models.
Researchers engineered RNA micelles carrying gemcitabine, survivin-targeting siRNA and a tumor-binding ligand. In mice with ...
Apart from carrying the information to encode proteins in, RNA molecules can adopt intricate 2D and 3D structures. Specifically, the same RNA molecule can switch between ON and OFF structures, ...
A new study in mice hints at the potential to use tiny particles made with RNA molecules to deliver chemotherapy drugs and ...
The RestorAATion-2 trial is ongoing and Wave expects to share multidose data in 2025. "Achieving the first-ever therapeutic RNA editing in humans is a significant milestone for our organization, for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results